Search results for "OUTCOME"

showing 10 items of 5148 documents

Long-term functional and psychological recovery in a population of acute respiratory distress syndrome patients treated with VV-ECMO and in their car…

2019

Background Acute respiratory distress syndrome (ARDS) survivors are affected with long-term physical/mental impairments, with improvements limited mostly to the first year after intensive care (ICU) discharge. Furthermore, caregivers of ICU patients exhibit psychological problems after family-member recovery. We evaluated the long-term physical and mental recovery of ARDS survivors treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO), and the long-term psychological impact on their caregivers. Methods Single-center prospective evaluation of a retrospective cohort of 75 ARDS patients treated with VV-ECMO during a seven-year period (25.10.2009-11.08.2016). Primary outcomes w…

AdultMaleARDSPediatricsmedicine.medical_specialtyPopulationAnxietyStress Disorders Post-Traumatic03 medical and health sciences0302 clinical medicineExtracorporeal Membrane OxygenationTracheostomyQuality of life030202 anesthesiologyIntensive careMedicineHumansSurvivorseducationDepression (differential diagnoses)Retrospective StudiesPatient health questionnaireeducation.field_of_studyPsychological TestsRespiratory Distress Syndromebusiness.industryDepression030208 emergency & critical care medicineRetrospective cohort studyRecovery of FunctionLength of StayMiddle Agedmedicine.diseasePatient Health QuestionnaireCritical careAnesthesiology and Pain MedicineTreatment OutcomeCaregiversQuality of LifeAnxietyFemalemedicine.symptombusinessFollow-Up StudiesMinerva anestesiologica
researchProduct

Diagnosis, treatment and long-term outcomes of autoimmune pancreatitis in Spain based on the International Consensus Diagnostic Criteria: A multi-cen…

2015

Abstract Objectives Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that has been reported worldwide for the last two decades. The aim of this study is to analyse the clinical profile of patients from Spain with AIP, as well as treatments, relapses and long-term outcomes. Methods Data from 59 patients with suspected AIP that had been diagnosed in 15 institutions are retrospectively analysed. Subjects are classified according to the International Consensus Diagnostic Criteria (ICDC). Patients with type 1 AIP (AIP1) and type 2 AIP (AIP2) are compared. Kaplan–Meier methodology is used to estimate the overall survival without relapses. Results Fifty-two patients met ICDC, 45 pat…

AdultMaleAbdominal painmedicine.medical_specialtyPathologyConsensusEndocrinology Diabetes and MetabolismKaplan-Meier EstimateDisease-Free SurvivalAutoimmune Diseases03 medical and health sciences0302 clinical medicineInternal medicinePancreatitis ChronicmedicineCombined Modality TherapyHumansPancreatitis chronicMulti centreAutoimmune pancreatitisAgedRetrospective StudiesHepatologybusiness.industryGastroenterologyRetrospective cohort studyMiddle Agedmedicine.diseaseCombined Modality TherapyTreatment OutcomeDiagnosis treatmentSpain030220 oncology & carcinogenesisPractice Guidelines as TopicPancreatitis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessFollow-Up StudiesPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
researchProduct

Assessment of EVAR Complications using CIRSE Complication Classification System in the UK Tertiary Referral Centre: A ∼6-Year Retrospective Analysis …

2021

Purpose: To retrospectively analyse complications in endovascular aortic repair (EVAR) interventions and evaluate if the CIRSE (Cardiovascular and Interventional Radiological Society of Europe) complication classification system is appropriate as a standardized classification tool for EVAR patients. Materials and Methods: Demographic, procedural and complication data in 719 consecutive patients undergoing EVAR at one institution from January 2014 to October 2019 were retrospectively reviewed. Data (imaging reports, procedural reports, nurse notes, discharge summary reports) were collected consulting the electronic patient record system (EPR) of the hospital and cleaned and stored in a Micro…

AdultMaleAccess-site complicationmedicine.medical_specialtyTime FactorsAdditional treatmentEndoleakEndovascular aortic repair (EVAR)Tertiary referral centreComplication grading scalePopulationVascular accessRadiology InterventionalSeverity of Illness Index030218 nuclear medicine & medical imagingTertiary Care Centers03 medical and health sciencesYoung Adult0302 clinical medicinePostoperative ComplicationsmedicineRetrospective analysisHumansRadiology Nuclear Medicine and imagingIn patienteducationReferral and ConsultationSocieties MedicalAgedRetrospective StudiesAged 80 and overeducation.field_of_studyCIRSE complication classification systemmedicine.diagnostic_testbusiness.industryGeneral surgeryEndovascular ProceduresInterventional radiologyMiddle AgedUnited KingdomAortic AneurysmEuropeReporting systemTreatment OutcomeRadiological weaponFemaleCardiology and Cardiovascular MedicineComplicationbusinessCardiovascular and interventional radiology
researchProduct

Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Reg…

2019

Aims In recent years, stroke prevention in patients with atrial fibrillation (AF) has radically changed, with increasing use of non-vitamin K antagonist oral anticoagulants (NOACs). Contemporary European data on AF thromboprophylaxis are needed. Methods and results We report 1-year follow-up data from the EURObservational Research Programme in Atrial Fibrillation (EORP-AF) General Long-Term Registry. Outcomes were assessed according to antithrombotic therapy. At 1-year follow-up, 9663 (88.0%) patients had available data for analysis: 586 (6.1%) were not treated with any antithrombotic; 681 (7.0%) with antiplatelets only; 4066 (42.1%) with vitamin K antagonist (VKA) only; 3167 (32.8%) with …

AdultMaleAcute coronary syndromemedicine.medical_specialtymedicine.drug_classHemorrhageOutcomes030204 cardiovascular system & hematologyLower riskRisk Assessment[SHS]Humanities and Social Sciences03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsPhysiology (medical)Internal medicineCause of DeathAntithromboticMedicineHumans030212 general & internal medicineProspective StudiesRegistriesPractice Patterns Physicians'StrokeAgedEORP-AF registryAged 80 and overAntithrombotic therapybusiness.industryProportional hazards modelAtrial fibrillationVitamin K antagonistMiddle Agedmedicine.diseaseAtrial fibrillationObservational registriesEuropeStrokeFemaleCardiology and Cardiovascular MedicinebusinessAntithrombotic therapy; Atrial fibrillation; EORP-AF registry; Observational registries; Outcomes; StrokeFibrinolytic agentFollow-Up Studies
researchProduct

Treatment of painful radiculopathies with capsaicin 8% cutaneous patch.

2017

The treatment of neuropathic pain due to low-back (lumbosacral) radiculopathies, a common source of neuropathic pain, is challenging and often requires a multimodal therapeutic approach. The capsaicin 8% patch is the first topical analgesic licensed for peripheral neuropathic pain. To evaluate this treatment, a subset of patients with painful radiculopathy (lumbar and cervical, including ventral and dorsal rami) enrolled into the multicenter, non-interventional QUEPP study (QutenzaOf the 1044 study participants, 50 were diagnosed with painful radiculopathy as only peripheral neuropathic pain syndrome and were eligible for evaluation. Patients received a single treatment (visit 1) with follo…

AdultMaleAdministration Cutaneous03 medical and health sciences0302 clinical medicineLumbarQuality of life030202 anesthesiologySurveys and QuestionnairesMedicineHumansRadiculopathyAgedReferred painbusiness.industryPruritusGeneral MedicineMiddle Agedmedicine.diseaseLow back painSpineTreatment OutcomeAnesthesiaNeuropathic painNeuralgiaQuality of LifeNeuralgiaFemalemedicine.symptomCapsaicinbusinessRadiculopathies030217 neurology & neurosurgeryLumbosacral jointCurrent medical research and opinion
researchProduct

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.

2010

BACKGROUND: One of the major goals of pemphigus therapy is to reduce the patient's cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. OBSERVATIONS: Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

AdultMaleAdministration OralMiddle AgedMycophenolic AcidTreatment OutcomeSettore MED/35 - Malattie Cutanee E VenereeEnteric-coated Mycophenolate SodiumHumansPrednisoneDrug Therapy CombinationFemaleTablets Enteric-CoatedGlucocorticoidsImmunosuppressive AgentsPemphigusFollow-Up StudiesInternational journal of dermatology
researchProduct

Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics

2002

Background: Antibodies to soluble liver antigen/liver pancreas (SLA/LP) are specific markers of autoimmune hepatitis. Their target antigen has recently been cloned. Aims: To establish standardised immunoassays using the recombinant antigen, and to assess the frequency and significance of seropositivity in patients from different countries. Methods: An enzyme linked immunoassay was developed using purified recombinant antigen and validated by testing sera from 200 healthy blood donors and 1026 patients with various liver and non-liver diseases. The assay was then applied to 454 sera from 419 patients with autoimmune hepatitis from different countries. All sera were also tested by inhibition …

AdultMaleAdolescentEnzyme-Linked Immunosorbent AssayAutoimmune hepatitisSensitivity and Specificitylaw.inventionJapanMaintenance therapyAntigenRecurrencelawGermanymedicineHumansChildAutoimmune diseaseHepatitisbiologymedicine.diagnostic_testbusiness.industryLiver DiseasefungiHistocompatibility Antigens Class IHistocompatibility Antigens Class IIInfant NewbornGastroenterologyAntibodies MonoclonalInfantmedicine.diseaseRecombinant ProteinsUnited StatesHepatitis AutoimmuneTreatment OutcomeChild PreschoolImmunoassayImmunologybiology.proteinRecombinant DNAFemaleAntibodybusinessBiomarkersBrazilGut
researchProduct

Management of primary ameloblastoma of the jaw: a 15 years' experience.

2012

AIM: The aim of this retrospective study was to describe our 15-year experience in the management of primary ameloblastoma of the jaw. METHODS: We investigated 26 patients who had undergone surgical treatment for a single lesion, comprising six lesions of the maxillary bone and 20 tumors of the mandible: 73% had a radiolucent multilocular lesion; 23% a unicystic lesion; and 4% had an extraosseous form of the tumor. The smaller lesions (diameter <3 cm) were treated by conservative approaches; the larger lesions required radical surgical resection. Two groups were created according to whether the patients had received conservative or aggressive surgery. RESULTS: The recurrence rate was estima…

AdultMaleAdolescentEstheticsAge FactorsMiddle AgedPlastic Surgery ProceduresJaw NeoplasmsSettore MED/29 - Chirurgia MaxillofaccialeCurettageOsteotomyAmeloblastomaRadiographyYoung AdultTreatment OutcomeSettore MED/28 - Malattie OdontostomatologicheHumansFemaleNeoplasm Recurrence LocalChildameloblastoma general surgery surgery oralFollow-Up StudiesRetrospective StudiesMinerva stomatologica
researchProduct

Evaluation of the prognostic role of tumour-associated macrophages in newly diagnosed classical hodgkin lymphoma and correlation with early FDG-PET a…

2017

In Hodgkin Lymphoma (HL), about 20% of patients still have relapsed/refractory disease and late toxic effects rate continue to rise with time. 'Early FDG-PET' and tissue macrophage infiltration (TAM) emerged as powerful prognostic predictors. The primary endpoint was to investigate the prognostic role of both early FDG-PET and TAM; the secondary endpoint was to test if early FDG-PET positivity could correlate with high TAM score. A cohort of 200 HL patients was analysed. Induction treatment plan consisted of two to six courses of ABVD and, if indicated, involved field radiation therapy. All patients repeated CT scan and FDG-PET after two cycles and after the completion of therapy. TAM in di…

AdultMaleAdolescentHodgkin’s lymphomaMacrophagePrognosiAntigens Differentiation MyelomonocyticVinblastineDisease-Free SurvivalCohort StudiesBleomycinYoung AdultAntigens CDFluorodeoxyglucose F18RecurrencePositron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsHumansCD68AgedAged 80 and overHodgkin's lymphomahematologyMacrophagesCD68; Hodgkin's lymphoma; macrophages; PET; prognosis; hematology; oncology; cancer researchAntibodies MonoclonalMiddle AgedPrognosisHodgkin DiseaseImmunohistochemistryDacarbazineTreatment OutcomePETDoxorubicinPositron-Emission Tomographyoncologycancer researchFemaleNeoplasm Recurrence LocalFollow-Up Studies
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.

2012

Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naïve patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400 mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44.2% of Peg-…

AdultMaleAdolescentInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultSex FactorsRibaviringenderHumansAgedSettore MED/12 - GastroenterologiaPeg IFNAge FactorsInterferon-alphaHepatitis C ChronicMiddle Agedcentral fat distribution cytokines metabolic syndrome pharmacokinetics sustained virological responseRecombinant ProteinsTreatment OutcomeDrug Therapy CombinationFemaleEpatite HCV; Peg IFN; genderMenopauseSettore SECS-S/01 - StatisticaEpatite HCVJournal of viral hepatitis
researchProduct